Aspirin therapy and thromboxane biosynthesis in systemic lupus erythematosus

Incomplete suppression of thromboxane biosynthesis during aspirin therapy is associated with increased cardiovascular risk. Since systemic lupus erythematosus (SLE) is associated with platelet activation and increased cardiovascular mortality, we compared thromboxane and prostacyclin biosynthesis in...

Full description

Saved in:
Bibliographic Details
Published in:Lupus 2007-01, Vol.16 (12), p.981-986
Main Authors: Avalos, Ingrid, Chung, Cecilia P., Oeser, Annette, Milne, Ginger L., Borntrager, Holly, Morrow, Jason D., Raggi, Paolo, Solus, Joseph, Stein, C. Michael
Format: Article
Language:English
Subjects:
Adult
Aspirin - pharmacology
Cyclooxygenase Inhibitors - pharmacology
Drug Resistance
Epoprostenol - metabolism
Female
Humans
Lupus Erythematosus, Systemic - drug therapy
Male
Middle Aged
Thromboxane A2 - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Incomplete suppression of thromboxane biosynthesis during aspirin therapy is associated with increased cardiovascular risk. Since systemic lupus erythematosus (SLE) is associated with platelet activation and increased cardiovascular mortality, we compared thromboxane and prostacyclin biosynthesis in patients with SLE and control subjects, and measured inhibition of thromboxane excretion in aspirin-treated subjects. We measured the urinary excretion of 11-dehydro thromboxane B 2 (TXB2) and 2,3-dinor 6-ketoPGF1α (PGI-M), the stable metabolites of thromboxane A2 and prostacyclin, respectively, in 74 patients with SLE and 70 controls. In subjects who were not receiving aspirin, TXB2 excretion was higher in patients with SLE [0.40 ng/mg creatinine (0.26—0.64), median (interquartile range)] than controls [0.31 ng/mg creatinine (0.23—0.44)] (P = 0.04), and in these patients, TXB2 excretion correlated with disease activity (rho = 0.28, P = 0.03) and tumor necrosis factor alpha (rho = 0.48, P < 0.001). Aspirin therapy resulted in significantly lower TXB2 excretion in controls (P = 0.01), but not in patients with SLE (P = 0.10), compared with subjects not receiving aspirin. Prostacyclin biosynthesis did not differ among patients and controls, and was not affected by aspirin (P all >0.35). Thromboxane biosynthesis is increased in SLE and is associated with disease activity. Additionally, response to aspirin may be attenuated in some patients with SLE. Lupus (2007) 16, 981—986.
ISSN:0961-2033
1477-0962
DOI:10.1177/0961203307083313